|Table of Contents|

Progress in research of thyroid cancer and AP-1

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 06
Page:
1076-1079
Research Field:
Publishing date:

Info

Title:
Progress in research of thyroid cancer and AP-1
Author(s):
Xiao Cheng; Liu Zhen
Department of Pancreatic Endocrine Surgery,Shengjing Hospital Affiliated to China Medical University,Liaoning Shenyang 110000,China.
Keywords:
AP-1; MAPK; thyroid cancer
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2019.06.042
Abstract:
Thyroid cancer is a common tumor of the endocrine system,and its pathogenesis has not been studied clearly.In recent years,studies on activator protein 1 (AP-1) and thyroid cancer have gradually increased.BRAF,RET,RAS,other gene mutations,cytokines,peptide hormones and other factors activate MAPK signaling pathway,promote transcription of Fos,Jun and other genes,and increase AP-1 expression.Over expression of AP-1 in thyroid cancer can activate downstream target genes such as VEGF,MMP-9,Cyclin D1,Fas,etc.,and play an crucial role in the process of proliferation,transformation,metastasis and apoptosis of thyroid cancer.This paper briefly reviews the progress of study between AP-1 and thyroid cancer.

References:

［1］ A Kharman-Biz,H Gao,R Ghiasvand,et al.Expression of activator protein-1 (AP-1) family members in breast cancer［J］.BMC Cancer,2013,13(1):441.
［2］ M Wang,L Li,J Liu,et al.A gene interaction network-based method to measure the common and heterogeneous mechanisms of gynecological cancer［J］.Molecular Medicine Reports,2018,18(1):230-242.
［3］ CY Lin,A Chao,TH Wang,et al.A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer［J］.J Mol Med (Berl),2014,92(9):969-981.
［4］ C Tang,Y Jiang,W Shao,et al.Abnormal expression of FOSB correlates with tumor progression and poor survival in patients with gastric cancer［J］.Int J Oncol,2016,49(4):1489-1496.
［5］ AC Mar,CH Chu,HJ Lee,et al.Interleukin-1 receptor type 2 acts with c-Fos to enhance the expression of interleukin-6 and vascular endothelial growth factor A in colon cancer cells and induce angiogenesis［J］.The Journal of Biological Chemistry,2015,290(36):22212-22224.
［6］ S Liu,J Luan,Y Ding.MiR-144-3p targets FosB protooncogene,AP-1 transcription factor subunit (FOSB) to suppress proliferation,migration,and invasion of PANC-1 pancreatic cancer cells［J］.Oncology Research,2018,26(5):683-690.
［7］ X Chen,W Wu,X Chen,et al.Roles of phosphatidylinositol 3-kinase regulatory subunit alpha,activator protein-1,and programmed cell death 4 in diagnosis of papillary thyroid carcinoma［J］.Tumour Biology,2016,37(5):6519-6526.
［8］ J Ma,SH Xuan,Y Li,et al.Role of the TGFbeta/PDCD4/AP-1 signaling pathway in nasopharyngeal carcinoma and its relationship to prognosis［J］.Cellular Physiology and Biochemistry,2017,43(4):1392-1401.
［9］ Garces De Los Fayos Alonso Ines,Huan Chang Liang,Suzanne D Turner,et al.The role of activator protein-1 (AP-1) family members in CD30-positive lymphomas［J］.Cancers,2018,10(4):93.
［10］ A Wang,M Al-Kuhlani,SC Johnston,et al.Transcription factor complex AP-1 mediates inflammation initiated by Chlamydia pneumoniae infection［J］.Cell Microbiol,2013,15(5):779-794.
［11］ S Trop-Steinberg,Y Azar.AP-1 expression and its clinical relevance in immune disorders and cancer［J］.Am J Med Sci,2017,353(5):474-483.
［12］ N Ye,Y Ding,C Wild,et al.Small molecule inhibitors targeting activator protein 1 (AP-1)［J］.J Med Chem,2014,57(16):6930-6948.
［13］ A Vivacqua,D Bonofiglio,L Albanito,et al.17beta-estradiol,genistein,and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30［J］.Molecular Pharmacology,2006,70(4):1414-1423.
［14］ A Pines,N Bivi,C Vascotto,et al.Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells:a novel tumorigenic pathway［J］.Journal of Cellular Physiology,2006,209(1):44-55.
［15］ J Zhong,C Liu,QH Zhang,et al.TGF-beta1 induces HMGA1 expression:The role of HMGA1 in thyroid cancer proliferation and invasion［J］.Int J Oncol,2017,50(5):1567-1578.
［16］ ZY Wu,SM Wang,ZH Chen,et al.MiR-204 regulates HMGA2 expression and inhibits cell proliferation in human thyroid cancer［J］.Cancer Biomark,2015,15(5):535-542.
［17］ D Vallone,S Battista,GM Pierantoni,et al.Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product［J］.Embo Journal,1997,16(17):5310.
［18］ S Battista,Nigris F De,M Fedele,et al.Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo［J］.Oncogene,1998,17(3):377-385.
［19］ G Chiappetta,G Tallini,MC De Biasio,et al.FRA-1 expression in hyperplastic and neoplastic thyroid diseases［J］.Clinical Cancer Research,2000,6(11):4300.
［20］ YH Kim,JH Oh,NH Kim,et al.Fra-1 expression in malignant and benign thyroid tumor［J］.Korean J Med,2000,59(4):398-403.
［21］ Sun HY,Xu XF.Advances in studying of thyroid papillary carcinoma related genes BRAF,p27 and Cyclin D1［J］.International Journal of Dermatology and Venereology,2015,39(1):30-33.［孙海勇,徐先发.甲状腺乳头状癌相关基因BRAF、p27、Cyclin D1研究进展［J］.国际耳鼻咽喉头颈外科杂志,2015,39(1):30-33.］
［22］ Zong S,Wang J,Wang Y,et al.Analysis of 179 BRAFV600E mutation in papillary thyroid carcinoma patients［J］.Modern Oncology,2017,25(13):2052-2054.［宗书,汪静,王悦,等.179例甲状腺乳头状癌患者BRAF(V600E)基因突变回顾性分析［J］.现代肿瘤医学,2017,25(13):2052-2054.］
［23］ R Liu,T Zhang,G Zhu,et al.Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer［J］.Nature Communications,2018,9(1):579.
［24］ HJ Kim,KR Kim,HS Park,et al.The expression and role of serum response factor in papillary carcinoma of the thyroid［J］.International Journal of Oncology,2009,35(1):49-55.
［25］ V Poulaki,CS Mitsiades,C McMullan,et al.Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas［J］.The Journal of Clinical Endocrinology and Metabolism,2003,88(11):5392-5398.
［26］ S Selemetjev,S Savin,I Paunovic,et al.Concomitant high expression of survivin and vascular endothelial growth factor-C is strongly associated with metastatic status of lymph nodes in papillary thyroid carcinoma［J］.J Cancer Res Ther,2018,14(Supplement):S114-S119.
［27］ XQ Huang,WS He,HQ Zhang,et al.Relationship between expression of vascular endothelial growth factor and cervical lymph node metastasis in papillary thyroid cancer:A meta-analysis［J］.J Huazhong Univ Sci Technolog Med Sci,2017,37(5):661-666.
［28］ S Selemetjev,I Ethoric,I Paunovic,et al.Coexpressed high levels of VEGF-C and active MMP-9 are associated with lymphatic spreading and local invasiveness of papillary thyroid carcinoma［J］.Am J Clin Pathol,2016,146(5):594-602.
［29］ LL Huang,Z Wang,CJ Cao,et al.AEG-1 associates with metastasis in papillary thyroid cancer through upregulation of MMP2/9［J］.Int J Oncol,2017,51(3):812-822.
［30］ MJ Park,MS Kim,IC Park,et al.PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation［J］.Cancer Research,2002,62(21):6318-6322.
［31］ YS Li,ZH Deng,C Zeng,et al.JNK pathway in osteosarcoma:pathogenesis and therapeutics［J］.J Recept Signal Transduct Res,2016,36(5):465-470.
［32］ Ma P,Wang XW,Li LH,et al.Effects of miR-34 on the biological behavior of thyroid carcinoma cells through regulating c-Jun protein［J］.Modern Oncology,2018,26(02):173-177.［马沛,汪旭伟,李连海,等.miR-34调控c-Jun蛋白对甲状腺癌细胞生物学行为的影响［J］.现代肿瘤医学,2018,26(02):173-177.］
［33］ X Zhou,T Hong,Q Yu,et al.Exopolysaccharides from Lactobacillus plantarum NCU116 induce c-Jun dependent Fas/Fasl-mediated apoptosis via TLR2 in mouse intestinal epithelial cancer cells［J］.Scientific Reports,2017,7(1):14247.
［34］ CS Mitsiades,D McMillin,V Kotoula,et al.Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro［J］.The Journal of Clinical Endocrinology and Metabolism,2006,91(10):4013-4021.
［35］ Cléber P Camacho,Flavia RM Latini,Gisele Oler,et al.Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment［J］.Clinical Endocrinology,2009,70(3):475-483.
［36］ M Guan,G Romano,R Coroniti,et al.Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm［J］.Journal of Experimental & Clinical Cancer Research,2014,33(1):1-11.
［37］ PR Bhargav,A Mishra,G Agarwal,et al.Long-term outcome of differentiated thyroid carcinoma:experience in a developing country［J］.World J Surg,2010,34(1):40-47.
［38］ V Subbiah,RJ Kreitman,ZA Wainberg,et al.Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer［J］.Journal of Clinical Oncology,2018,36(1):JCO2017736785.
［39］ J Wendler,M Kroiss,K Gast,et al.Clinical presentation,treatment and outcome of anaplastic thyroid carcinoma:Results of a multicenter study in Germany［J］.European Journal of Endocrinology,2016,175(6):521-529.

Memo

Memo:
National Natural Science Foundation of China(No.81672644);国家自然科学基金资助项目（编号：81672644）
Last Update: 1900-01-01